SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Valuation After New Sugemalimab Indication And US Phase II Trial Clearance
CStone Pharmaceuticals (SEHK:2616) has been in focus after fresh regulatory progress for its lead cancer drug sugemalimab, along with a new U.S. trial clearance that extends its immunotherapy pipeline into advanced solid tumors.
See our latest analysis for CStone Pharmaceuticals.
Those approvals for sugemalimab and the U.S. FDA clearance for a new Phase II trial have arrived alongside strong momentum, with a 30 day share price return of 24.39% and a 1 year total shareholder return of 94.75%...